Topical piroxicam in vitro release and in vivo anti- inflammatory and analgesic effects from palm oil esters-based nanocream

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 915-924

  Abdulkarim, Muthanna F ^a   Abdullah, Ghassan Z ^a   Chitneni, Mallikarjun ^b   Salman, Ibrahim M ^a   Ameer, Omar Z ^a   Yam, Mun F ^a,c   Mahdi, Elrashid S ^a   Sattar, Munavvar A ^a   Basri, Mahiran ^c   Noor, Azmin M ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Analgesic; Anti inflammatory; Nanocream; Piroxicam; Skin permeation

Indexed keywords

PALM OIL; PIROXICAM; ANALGESIC AGENT; NANOMATERIAL; NONSTEROID ANTIINFLAMMATORY AGENT; VEGETABLE OIL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED STUDY; CREAM; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; GEL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PAIN; PAW EDEMA; PHARMACODYNAMICS; RAT; STEADY STATE; ACTIVE TRANSPORT; ANIMAL; CHEMISTRY; DRUG EFFECT; ESTERIFICATION; METABOLISM; NANOMEDICINE; PAIN THRESHOLD; PATHOLOGY; PERMEABILITY; SKIN; TOPICAL DRUG ADMINISTRATION;

RATTUS;

ADMINISTRATION, TOPICAL; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL TRANSPORT, ACTIVE; ESTERIFICATION; MEMBRANES, ARTIFICIAL; NANOMEDICINE; NANOSTRUCTURES; PAIN THRESHOLD; PERMEABILITY; PIROXICAM; PLANT OILS; RATS; SKIN;

EID: 79952118153     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S13305     Document Type: Article

References (57)

1. Jinno J, Oh DM, Crison JR, Amidon GL. Dissolution of ionizable water-insoluble drugs: The combined effect of pH and surfactant. Int J Pharm. 2000;89:268-274.
2. Mihalic M. Piroxicam. Analytical Profiles of Drug Substances. 1986;15:23.
3. MS, Cross SE. Percutaneous absorption of topically applied NSAIDs and other compounds: Role of solute properties, skin physiology and delivery systems. Inflammopharmacology. 1999;7:339-350.
4. Goosen C, Plessis JD, Müller DG, Janse van Rensburg LF. Correlation between physicochemical characteristics, pharmacokinetic properties and transdermal absorption of NSAIDs. Int J Pharm. 1998;163:203-209.
5. Beetge E, Plessis JD, Müller DG, Goosen C, van Rensburg FJ. The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAIDs on their transdermal absorption. Int J Pharm. 2000;193:261-264.
6. Hadgraft J, Plessis JD, Goosen C. The selection of non-steroidal anti-inflammatory agents for dermal delivery. Int J Pharm. 2000;207: 31-37.
7. Cheong HA, Choi HK. Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm Res. 2002;19: 1375-1380.
8. Huang YB, Wu PC, Ko HM, Tsai YH. Effect of pretreatment by cardamom oil on in vivo percutaneous absorption of piroxicam gel: Pharmacokinetic analysis in rabbits. Int J Pharm. 1996;134:183-191.
9. Hsu LR, Tsai YH, Huang YB. The effect of pretreatment by penetration enhancers on the in vivo percutaneous absorption of piroxicam from its gel form in rabbits. Int J Pharm. 1991;71:193-200.
10. Santoyo S, Arellano A, Ygartua P, Martin C. Penetration enhancer effects on the in vitro percutaneous absorption of piroxicam through rat skin. Int J Pharm. 1995;117:219-224.
11. Santoyo S, Ygartua P. Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application. Eur J Pharm Biopharm. 2000;50:245-250.
12. Pénzes T, Blazsó G, Aigner Z, Falkay G, Eros I. Topical absorption of piroxicam from organogels - in vitro and in vivo correlations. Int J Pharm. 2005;298:47-54.
13. Shin SC, Cho CW, Oh IJ. Enhanced eff icacy by percutaneous absorption of piroxicam from the poloxamer gel in rats. Int J Pharm. 2000;193:213-218.
14. Curdy C, Kalia YN, Naik A, Guy RH. Piroxicam delivery into human stratum corneum in vivo: Iontophoresis versus passive diffusion. J Control Release. 2001;76:73-79.
15. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 2002;54:S77-98.
16. Keng PS, Basria M, Zakaria MRS, et al. Newly synthesized palm esters for cosmetics industry. Ind Crops Prod. 2009;29:37-44.
17. Abdulkarim MF, Abdullah GZ, Chitneni M, et al. Formulation and characterization of palm oil esters based nano-cream for topical delivery of piroxicam. Int J Drug Deliv. 2010;2:287-298.
18. Abdulkarim MF, Abdullah GZ, Chitneni M, et al. Stability studies of nano-cream containing piroxicam. Int J Drug Deliv. 2010;2: 333-339.
19. Djordjevic J, Michniak B, Uhrich KE. Amphiphilic star-like macromolecules as novel carriers for topical delivery of non-steroidal anti- Inflammatory drugs. AAPS PharmSciTech. 2003;5:1-12.
20. Ng SF, Rouse J, Sanderson D, Eccleston GA. Comparative study of trans-membrane diffusion and permeation of ibuprofen across synthetic membranes using Franz diffusion cells. Pharmaceutics. 2010; 2:209-223.
21. Özgüney IS, Karasulu HY, Kantarc G, Sözer S, Güneri T, Ertan G. Transdermal delivery of diclofenac sodium through rat skin from various formulations. AAPS PharmSciTech. 2006;7(4):E1-E7.
22. Singh S, Gajra B, Rawat M, Muthu MS. Enhanced transdermal delivery of ketoprofen from bioadhesive gels. Pak J Pharm Sci. 2009;22: 193-198.
23. Wagner H, Kostka KH, Lehr CM, Schaefer UF. Interrelation of permeation and penetration parameters obtained from in vitro experiments with human skin and skin equivalents. J Control Release. 2001;75:283-295.
24. Larson DL, Lombardino JG. The topical anti-inflammatory effects of piroxicam in rodents. Agents Actions. 1980;10:246-252.
25. Yam MF, Lim V, Salman IM, et al. HPLC and anti-inflammatory studies of the flavonoid rich chloroform extract fraction of Orthosiphon stamineus leaves. Molecules. 2010;15:4452-4466.
26. Yam MF, Ang LF, Ameer OZ, Salman IM, Aziz HA, Asmawi MZ. Anti-inflammatory and analgesic effects of Elephantopus tomentosus ethanolic extract. J Acupunct Meridian Stud. 2009;2:280-287.
27. Guy RH, Hadgraft J. On the determination of drug release rates from topical dosage forms. Int J Pharm. 1990;60:R1-R3.
28. Shah VP, Elkins J, Lam SY, Skelly JP. Determination of in vitro drug release from hydrocortisone creams. Int J Pharm. 1989;53:53-59.
29. Dalmora ME, Dalmora SL, Oliveira AG. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm. 2001;222:45-55.
30. Gupta PK, Cannon JB. Emulsion and micro-emulsion for drug solubilization and delivery. In: Liu R, editor. Water-insoluble Drug Formulation. New York, NY: CRC Press; 2000.
31. Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2006;315:52-58.
32. Abdullah GZ, Abdulkarim MF, Chitneni M, et al. Preparation and in vitro evaluation of mebeverine HCl colon-targeted drug delivery system. Pharm Dev Technol. April 30, 2010. [Epub ahead of print].
33. ® polymer gels for the topical delivery of oxygen/water sensitive compounds. Pharm Dev Technol. 2002;7:249-255.
34. Wester RC, Noonan PK. Relevance of animal models for percutaneous absorption. Int J Pharm. 1980;7:99-110.
35. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: Overcoming the skin's barrier function. Pharm Sci Technolo Today. 2000;3: 318-326.
36. Walters KA, Roberts MS. Veterinary applications of skin penetration enhancers. In: Walters KA, Hadgraft J, editors. Pharmaceutical Skin Penetration Enhancement. New York, NY: Marcel Dekker; 1993.
37. Santoyo S, Arellano A, Ygartua P, Martin C. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Pharm Acta Helv. 1996;71:141-146.
38. Tanojo H, Bouwstra JA, Junginger HE, Boddé HE. In vitro human skin barrier modulation by fatty acids: Skin permeation and thermal analysis studies. Pharm Res. 1997;14:42-49.
39. Park E, Cui Y, Yun BJ, Ko IJ, Chi SC. Transdermal delivery of piroxicam using microemulsions. Arch Pharm Res. 2005;28:243-248.
40. Endo M, Yamamoto T, Ijuin T. Effect of nonionic surfactants on the percutaneous absorption of tenoxicam. Chem Pharm Bull. 1996;44: 865-867.
41. Okuyama H, Ikeda Y, Kasai S, Imamori K, Takayama K, Nagai T. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. Int J Pharm. 1999;186: 141-148.
42. ® on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm. 2000;202:133-140.
43. Shin SC, Cho CW, Oh IJ. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int J Pharm. 2001;222:199-203.
44. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Control Release. 2000;69:421-433.
45. Tsai YH, Hsu LR, Naito SI. Percutaneous absorption of piroxicam from ointment bases in rabbits. Int J Pharm. 1985;24:61-78.
46. Hadgraft J, Plessis JD, Goosen C. The selection of non-steroidal anti- inflammatory agents for dermal delivery. Int J Pharm. 2000;207:31-37.
47. Hadgraft J, Walters KA, Wotton PK. Facilitated percutaneous absorption: A comparison and evaluation of two in vitro models. Int J Pharm. 1986;32:257-263.
48. Green PG, Hadgraft J. Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid. Int J Pharm. 1987;37: 251-255.
49. Cheong HA, Choi HK. Effect of ethanolamine salts and enhancers on the percutaneous absorption of piroxicam from a pressure sensitive adhesive matrix. Eur J Pharm Sci. 2003;18:149-153.
50. Murthy SN, Zhao YL, Sen A, Hui SW. Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporation. J Control Release. 2004;99:393-402.
51. Hill JR, Wertz PW. Molecular models of the intercellular lipid lamellae from epidermal stratum corneum. Biochim Biophys Acta. 2003;1616: 121-126.
52. Mcneill SC, Potts RO, Francoeur ML. Local enhanced topical delivery (LETD) of drugs: Does it truly exist? Pharm Res. 1992;9:1422-1427.
53. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs. 2000;60:555-575.
54. Shargel L, Wu-Ping S, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. New York, NY: McGraw-Hill; 1999.
55. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech. 2007;8:E1-E9.
56. Veiga AP, Duarte ID, Avila MN, de Motta PG, Tatsuo MA, Francischi JN. Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004;75:2807-2817.
57. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283: 1069-1076.